Third Harmonic Bio Inc THRD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/18/24 EDT
11.43quote price arrow up+0.15 (+1.33%)
Volume
199,832
52 week range
4.06 - 12.42
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close11.43
  • 52 Week High12.42
  • 52 Week High Date04/11/24
  • 52 Week Low4.06
  • 52 Week Low Date04/26/23

Key Stats

  • Market Cap465.366M
  • Shares Out40.71M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change4.19

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close11.43
  • 52 Week High12.42
  • 52 Week High Date04/11/24
  • 52 Week Low4.06
  • 52 Week Low Date04/26/23
  • Market Cap465.366M
  • Shares Out40.71M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change4.19

RATIOS/PROFITABILITY

  • EPS (TTM)-0.95
  • P/E (TTM)-12.08
  • Fwd P/E (NTM)-9.00
  • EBITDA (TTM)-43.919M
  • ROE (TTM)-11.05%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/18/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Third Harmonic Bio Inc

 

Profile

MORE
Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is engaged in the development of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. It is focused on developing oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated...
Mark Iwicki
Independent Chairman of the Board
Natalie Holles
Chief Executive Officer, Director
Christopher Murphy
Chief Financial and Business Officer and Principal financial officer
Address
1700 Montgomery Street, Suite 210
San Francisco, CA
94111
United States

Top Peers

SYMBOLLASTCHG%CHG
LBPH
Longboard Pharmaceuticals Inc
18.01+1.01+5.94%
BMEA
Biomea Fusion Inc
11.16-0.34-2.96%
FULC
Fulcrum Therapeutics Inc
7.06-0.09-1.26%
LXRX
Lexicon Pharmaceuticals Inc
1.63+0.01+0.62%
LRMR
Larimar Therapeutics Inc
6.38-0.67-9.50%